Adult Growth Hormone Deficiency
Conditions
Interventions
1:Cross-sectional survey
Sponsors
Tai 'an City Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 65; 2. Stroke patients: Acute focal or comprehensive clinical symptom, neurologic deficits and duration of clinical symptoms and signs of the neurologic deficits for more than 24 hours, and to rule out other non vascular causes (such as primary brain tumor, subdural hematoma, brain metastases, brain injury after seizures, paralysis, etc.) caused by brain dysfunction, Skull MRI or CT confirmed focal hemorrhage or infarction [1, 2]. 3. When subjects signed the informed consent and entered the screening period, the time between stroke occurrence was more than 1 week and less than 26 weeks; The subject is willing and able to cooperate with the scheduled visit, treatment plan, laboratory examination and other test procedures, and sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Disturbance of consciousness during screening, including drowsiness, lethargy, coma, confusion, and delirium. 2. Pregnancy: For women with fertility potential, a negative pregnancy urine test is required. 3. Hba1c > 9.0% at screening. 4. Renal insufficiency (serum creatinine > 3.0 mg/dL) or end-stage renal disease. Kidney replacement therapy is required. Systolic blood pressure < 90mmHg and/or diastolic blood pressure < 50mmHg. 6. Ecg abnormalities of clinical significance that are considered inappropriate for inclusion in this study. 7. Not suitable for venipuncture. 8. Congestive heart failure, New York Heart Association (NYHA) Class III or IV. 9. History of seizures. 10. History of pheochromocytoma and/or islet tumor. 11. History of glycogen accumulation. 12. Participated in clinical trials of any drug or medical device within 3 months prior to screening (except those who signed informed consent only and did not receive any drug or device intervention) 13. Used growth hormone therapy in the past one year; Other reasons the researchers say need to be ruled out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine examination;Growth Hormone;IGF-1;Thyroid function five;Blood cortisol and ACTH ;Blood fat;Serum homocysteine;CRP;Fasting blood-glucose;Total glycaemic hemoglobin;Head CT and/or MRI;National Institute of Health stroke scale;Montreal Cognitive Assessment;Modified Rankin Scale, mRS;Self—Rating Anxiety Scale;Self-Rating Depresion Seale;Insulin Tolerance Test; | — |
Countries
China
Contacts
Public ContactZuncheng Zheng
Outcome results
None listed